B
Barbara J. Gitlitz
Researcher at University of Southern California
Publications - 93
Citations - 3214
Barbara J. Gitlitz is an academic researcher from University of Southern California. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 27, co-authored 82 publications receiving 2738 citations. Previous affiliations of Barbara J. Gitlitz include City of Hope National Medical Center & Genentech.
Papers
More filters
Journal ArticleDOI
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist,Benjamin Besse,Thomas J. Lynch,Vincent A. Miller,Kwok K. Wong,Barbara J. Gitlitz,Keith D. Eaton,Charles Zacharchuk,Amy Freyman,Christine Powell,Revathi Ananthakrishnan,Susan Quinn,Jean-Charles Soria +12 more
TL;DR: Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naïve patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.
Journal ArticleDOI
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B.Y. Ma,Wan-Teck Lim,Boon Cher Goh,Edwin P. Hui,Kwok Wai Lo,Adam Pettinger,Nathan R. Foster,Jonathan W. Riess,Mark Agulnik,Alex Y. Chang,Akhil Chopra,Julie A. Kish,Christine H. Chung,Douglas Adkins,Kevin J. Cullen,Barbara J. Gitlitz,D. Lim,Ka Fai To,K.C. Allen Chan,Y.M. Dennis Lo,Ann D. King,Charles Erlichman,Jun Yin,Brian A. Costello,Anthony T.C. Chan +24 more
TL;DR: Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations and the biomarker results were hypothesis generating and validation in larger cohorts is needed.
Journal ArticleDOI
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam,Michael L. Maitland,Paul Frankel,Athanassios Argiris,Marianna Koczywas,Barbara J. Gitlitz,Sachdev P. Thomas,Igor Espinoza-Delgado,Everett E. Vokes,David R. Gandara,Chandra P. Belani +10 more
TL;DR: Vorinostat enhances the efficacy of carboplatin and paclitaxel in patients with advanced NSCLC, and this phase II randomized, double-blinded, placebo-controlled study concludes that HDAC inhibition is a promising therapeutic strategy for treatment ofNSCLC.
Journal ArticleDOI
Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
Suresh S. Ramalingam,Chandra P. Belani,Christopher Ruel,Paul Frankel,Barbara J. Gitlitz,Marianna Koczywas,Igor Espinoza-Delgado,David R. Gandara,David R. Gandara +8 more
TL;DR: A phase II study of belinostat in patients with relapsed malignant pleural mesothelioma found that this novel inhibitor of class I and II histone deacetylases is not active as monotherapy against recurrent malignant psoriasis.
Journal ArticleDOI
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn,Jeffrey R. Infante,Karen L. Reckamp,George R. Blumenschein,Ticiana A. Leal,Saiama N. Waqar,Barbara J. Gitlitz,Rachel E. Sanborn,Jennifer G. Whisenant,Liping Du,Joel W. Neal,Jon P. Gockerman,Gary Dukart,K. Harrow,Chris Liang,James J. Gibbons,A. Holzhausen,Christine M. Lovly,Heather A. Wakelee +18 more
TL;DR: Ensartinib was active and generally well tolerated in patients with ALK-positive NSCLC, and Responses were also observed in the central nervous system.